Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Other Non-Current Assets (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Other Non-Current Assets for 14 consecutive years, with $267000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets fell 79.99% year-over-year to $267000.0, compared with a TTM value of $267000.0 through Dec 2025, down 79.99%, and an annual FY2025 reading of $267000.0, down 79.99% over the prior year.
  • Other Non-Current Assets was $267000.0 for Q4 2025 at Karyopharm Therapeutics, down from $350000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.3 million in Q4 2024 and bottomed at $267000.0 in Q4 2025.
  • Average Other Non-Current Assets over 5 years is $520850.0, with a median of $506500.0 recorded in 2022.
  • The sharpest move saw Other Non-Current Assets soared 343.19% in 2024, then crashed 79.99% in 2025.
  • Year by year, Other Non-Current Assets stood at $637000.0 in 2021, then fell by 0.63% to $633000.0 in 2022, then plummeted by 52.45% to $301000.0 in 2023, then skyrocketed by 343.19% to $1.3 million in 2024, then plummeted by 79.99% to $267000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for KPTI at $267000.0 in Q4 2025, $350000.0 in Q3 2025, and $350000.0 in Q2 2025.